BERKELEY, Calif. and VANCOUVER, British Columbia - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell's lead candidate Bria-IMT as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) and Incyte's retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation). HLA-Typing: Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body's immune response. BriaCell's immunotherapy treatment appears most effective when the patient's HLAtype matches with Bria-IMT, allowing BriaCell to potentially identify patients most likely to respond. HLA-typing is a simple and widely available test. Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for whom BriaCell's treatment would be most effective.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Forward Looking Statements

This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under 'Risks and Uncertainties' and in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Contact:

William V. Williams

MD President & CEO

T: 1-888-485-6340

E: info@briacell.com

(C) 2021 Electronic News Publishing, source ENP Newswire